Opendata, web and dolomites


Commercial feasibility of the Novio-PlainGel: a novel synthetic, reversible thermosensitive, biomimetic hydrogel for organoid-based precision medicine

Total Cost €


EC-Contrib. €






 OPTIMIsE project word cloud

Explore the words cloud of the OPTIMIsE project. It provides you a very rough idea of what is the project "OPTIMIsE" about.

clinical    stem    cancer    stage    membrane    small    later    excellent    unmet    optimal    thermosensitive    biomaterial    drug    models    extract    personalised    organs    mouse    proprietary    culturing    natural    tissue    gt    noviocell    commercial    builds    cumulative    variability    3d    performance    ease    matrigel    organoid    material    platform    ex    downstream    synthetic    diagnostic    pancreatic    optimise    introduction    initially    polyisocyanopeptide    disease    clinics    medicine    proof    bv    combination    hampered    feasibility    perform    standard    hydrogels    company    pic    risk    batch    organoids    matrices    biomechanics    reversible    profitability    transmission    innovative    sub    vivo    bio    spur    million    uniquely    sarcoma    revenues    basement    hydrogel    extracellular    possibilities    matrix    biotechnology    thermo    recovery    exponentially    precision    up    immunologic    sensitive    mini    pathogen    cultured    culture    cell    validation    market   

Project "OPTIMIsE" data sheet

The following table provides information about the project.


Organization address
address: KLOOSTERSTRAAT 9 RE1131
city: OSS
postcode: 5349 AB
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NOVIOCELL BV NL (OSS) coordinator 50˙000.00


 Project objective

Noviocell BV is a highly innovative biotechnology company and builds upon its proprietary polyisocyanopeptide (PIC) hydrogel. This is a novel synthetic, reversible thermosensitive hydrogel for 3D cell culturing. PIC hydrogels uniquely perform like a natural biomaterial, while being fully reversible thermo-sensitive, which allows for ease of cell/tissue recovery and easy downstream processing after culturing. In addition, PIC hydrogel has a unique combination of bio-functionality and biomechanics that makes them excellent matrices for 3D stem cell culture. During OPTIMIsE, Noviocell BV will investigate the technical and commercial feasibility of using the PIC hydrogel as a platform for the clinical use of organoids (mini organs ex vivo). The use of organoids in a clinical set-up has the potential to open up unique possibilities for precision medicine, as it can facilitate organoid-based drug testing and provide disease specific models. However, their clinical use is currently hampered because of batch-to-batch variability, sub-optimal extracellular matrix, small scale production and the risk of immunologic response and pathogen transmission (as they cultured in Matrigel which a basement membrane extract from mouse sarcoma). The PIC hydrogel, due to its unique characteristic, can address these unmet needs and facilitate the use of organoids for personalised medicine. The validation of PIC hydrogel initially as the best hydrogel for growing organoids (using pancreatic organoids as a proof of concept) and at a later stage as a diagnostic platform in clinics will spur the profitability and growth performance of Noviocell BV. It is estimated that within 5 years after market introduction of the PIC hydrogel, Noviocell BV will have cumulative revenues of >€40,7 million (only in the pancreatic cancer market). These revenues will exponentially increase when the PIC hydrogel will become the standard material for growing organoids.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPTIMISE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPTIMISE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More